Skip to main content
Premium Trial:

Request an Annual Quote

John DelliSanti, Robert Steininger

Premium
Caliper Life Sciences announced this week that John DelliSanti will be the company’s new executive vice president and chief commercial officer. In this position, DelliSanti will be in charge of Caliper’s worldwide sales, marketing and services efforts.
 
Prior to joining Caliper, DelliSanti led commercial operations at Invitrogen and held various positions at the chemical software and informatics company Accelrys.
 

 
Biopharmaceutical company Acceleron Pharma announced last week the appointment of Robert Steininger as senior VP of Manufacturing.
 
Previously, Steininger was VP of process sciences at Millennium Pharmaceuticals, and held multiple positions at Genetics Institute, now Wyeth Pharmaceuticals, from 1984 to 2000.

Filed under

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.